Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study

Abstract

Chronic inflammation has been indicated to be important in the pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). The systemic immune-inflammation index (SII) is a novel marker of inflammation. The present study was thus performed to explore the association between the SII at diagnosis and inflammatory response and disease activity in Chinese patients with myeloperoxidase (MPO)-AAV. Furthermore, it was evaluated whether the SII is able to predict the progression to end-stage renal disease (ESRD) and patient survival. A total of 190 patients with MPO-AAV were included in the present study. The baseline SII was positively correlated with C-reactive protein (CRP; r=0.274, P<0.0001) and the erythrocyte sedimentation rate (ESR; r=0.481, P<0.0001). However, the SII had no obvious correlation with the Birmingham vasculitis activity score. Patients with SII≥2,136.45 exhibited better cumulative renal survival rates than those with SII<2,136.45 (P=0.001). However, no significant difference in patient survival was indicated between patients with SII≥2,136.45 and those with SII<2,136.45 at diagnosis. In conclusion, the SII was positively correlated with CRP and ESR in Chinese patients with MPO-AAV. Furthermore, the SII may be an independent factor associated with a reduced risk of ESRD.

The effect of the pretreatment systemic immune-inflammatory index and C-reactive protein-to-albumin ratio on prognosis in pediatric patients with IgA vasculitis

“…It is because of this that many studies have been carried out for predicting visceral organ involvement, particularly in the GI and renal systems, using various indices and laboratory parameters. However, as far as we know, in recent studies, no assessment has been made regarding the place of SII and CAR in determining prognosis in illnesses such as cancer, MI, Behcet's Disease, and ANCA-associated vasculitis (15,19,20,(27)(28)(29). We found in our study that CAR was not significantly effective in determining prognosis for visceral involvement in patients with IgAV, but SII was a significant predictor of visceral involvement.…”

“…Previous studies have shown that the NLR value is higher in patients with renal and systemic involvement in IgAV than in patients without renal and systemic involvement (3,22,44,46). In recent years, SII, which uses neutrophils, platelets, and lymphocytes together, and the CAR index, which evaluates CRP and albumin together, have attracted the attention of researchers and been used to evaluate disease pathogenesis and severity of inflammation in many diseases (15,19,21,(27)(28)(29)(47)(48)(49)(50). Since CAR provides the opportunity to evaluate increased CRP and decreased serum albumin together in chronic inflammation, it has provided researchers with a twoway perspective.…”

“…In recent years, a new systemic immune-inflammation index (SII) (neutrophils x platelets/lymphocytes) based on lymphocyte, neutrophil, and platelet counts has been developed, and SII has been shown to be a potential prognostic indicator, especially in patients with malignancies (12). There are a limited number of studies related SII in rheumatic diseases (13)(14)(15). C-reactive protein (CRP) is a widely used acute phase protein that is regulated by proinflammatory cytokines.…”

Systemic immune-inflammation index and other inflammatory parameters in patients receiving biological or targeted synthetic DMARDs for inflammatory rheumatic disease

“…vasculitis, but post-treatment results were not analysed in these studies [14,[27][28][29][30]. To the best of our knowledge, this is the first study to evaluate SII in response to immunosuppressive therapy in rheumatic diseases.…”

A Novel Marker for Predicting Fulminant Myocarditis: Systemic Immune–Inflammation Index

“…The search for effective and appropriate prognostic biomarkers can help clinicians identify highrisk patients in a timely manner and make better medical decisions in clinical practice. The systemic immune-inflammation index (SII) as a new inflammatory index combining lymphocyte, neutrophil, and platelet count information has recently been proposed as a strong prognostic indicator of poor outcome in some in some inflammatory diseases (such as antineutrophil cytoplasmic antibody-associated vasculitis, Henoch-Schönlein Purpura) and neoplasms (such as lung cancer, hepatocellular carcinoma) [6][7][8][9].…”